Pharmacology of Nilotinib in the Treatment of Parkinson’s Disease Caused by New Pathology

Abstract

Parkinson’s disease (PD) is still not curable and controllable, which needs to find new pathology of PD and effective drugs to treat. To study the new pathology of PD, ten rats composed of half sex as an experimental group were injected with 5 μg α-synuclein monomer into the substantia nigra in every rats. In the second day after injection, the four main symptoms of PD appeared in the rats to demonstrate that the standard animal models of PD were established and lasted at least for more than 3 months or became deteriorating of PD. For the drug experiments of rats by using the same 5 μg α-synuclein injected into the substantia nigra, one week later, after the symptoms stabilized, every experimental rats were intraperitoneally administered with 0.3 mg nilotinib solution every morning once a day for 30 consecutive days. Importantly, these treatments could eliminate all symptoms of PD, and then the rats gradually showed no stiffness, shaking, foot flipping, or dragging and exhibited strong feet, the ability to walk and run, and smooth fur. After 30 days, treatments were stopped, and the rats continued to show no symptoms of PD and healthily survived. Since the symptoms of PD were induced by injecting 5 μg α-synuclein into the rats, now no symptoms of PD indicated the elimination of α-synuclein monomer in the rats under the help of nilotinib. The rat experimental results had demonstrated the PD caused by injecting 5 μg α-synuclein was a new pathological process by α-synuclein to block dopamine functional channels (DFCs) reducing the values of functionalization factor (f) and functional dopamine (GD) content, independent on the content of dopamine and the apoptosis of dopamine neurons in the rats. The pharmacology of nilotinib used to cure the PD caused by new pathology was by clearing α-synuclein to unblock DFCs and increase the values of f and GD content..